| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinson Disease | 55 | 2023 | 2775 | 5.140 |
Why?
|
| DNA, Mitochondrial | 26 | 2019 | 817 | 3.890 |
Why?
|
| Creatine | 6 | 2017 | 421 | 1.320 |
Why?
|
| Arthritis, Psoriatic | 5 | 2022 | 215 | 1.270 |
Why?
|
| DNA-Directed DNA Polymerase | 4 | 2015 | 486 | 1.180 |
Why?
|
| Caffeine | 3 | 2017 | 699 | 1.030 |
Why?
|
| MPTP Poisoning | 2 | 2014 | 35 | 0.940 |
Why?
|
| Thiolester Hydrolases | 1 | 2023 | 86 | 0.890 |
Why?
|
| Neuroprotective Agents | 4 | 2021 | 941 | 0.860 |
Why?
|
| Mitochondria | 10 | 2023 | 3514 | 0.780 |
Why?
|
| Psoriasis | 4 | 2022 | 902 | 0.780 |
Why?
|
| Oxidative Phosphorylation | 3 | 2013 | 481 | 0.780 |
Why?
|
| Duodenum | 1 | 2023 | 484 | 0.730 |
Why?
|
| Parkinsonian Disorders | 3 | 2016 | 275 | 0.710 |
Why?
|
| Eosinophilia | 1 | 2023 | 541 | 0.660 |
Why?
|
| Glycolysis | 2 | 2013 | 829 | 0.650 |
Why?
|
| Point Mutation | 7 | 2010 | 1624 | 0.640 |
Why?
|
| Disease Progression | 12 | 2021 | 13286 | 0.640 |
Why?
|
| Olfaction Disorders | 1 | 2021 | 222 | 0.630 |
Why?
|
| Mutation | 17 | 2019 | 29786 | 0.620 |
Why?
|
| Substantia Nigra | 7 | 2023 | 353 | 0.620 |
Why?
|
| Dystonic Disorders | 6 | 2011 | 329 | 0.600 |
Why?
|
| alpha-Synuclein | 5 | 2023 | 722 | 0.590 |
Why?
|
| Nortropanes | 1 | 2016 | 13 | 0.580 |
Why?
|
| Aging | 11 | 2015 | 8664 | 0.570 |
Why?
|
| Dopamine Agents | 3 | 2017 | 189 | 0.560 |
Why?
|
| Dopamine | 4 | 2014 | 1591 | 0.560 |
Why?
|
| Appendicitis | 1 | 2023 | 645 | 0.560 |
Why?
|
| Abdominal Pain | 1 | 2023 | 1064 | 0.560 |
Why?
|
| Lewy Body Disease | 2 | 2012 | 229 | 0.550 |
Why?
|
| Patient Care Management | 1 | 2019 | 306 | 0.540 |
Why?
|
| Superior Colliculi | 6 | 1992 | 99 | 0.530 |
Why?
|
| Intracranial Hypotension | 1 | 2015 | 41 | 0.520 |
Why?
|
| Movement Disorders | 2 | 2016 | 446 | 0.500 |
Why?
|
| Deoxyguanosine | 1 | 2015 | 84 | 0.500 |
Why?
|
| Antiparkinson Agents | 4 | 2022 | 184 | 0.490 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2021 | 17446 | 0.480 |
Why?
|
| Neuroacanthocytosis | 2 | 2023 | 6 | 0.470 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 2 | 2017 | 896 | 0.470 |
Why?
|
| Transcription Factors | 7 | 2020 | 12207 | 0.450 |
Why?
|
| Sodium Chloride | 1 | 2015 | 625 | 0.450 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2012 | 96 | 0.440 |
Why?
|
| Apoptosis Regulatory Proteins | 7 | 2011 | 1157 | 0.430 |
Why?
|
| Dystonia | 3 | 2008 | 363 | 0.430 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 476 | 0.400 |
Why?
|
| Neurotransmitter Agents | 1 | 2015 | 647 | 0.400 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 1107 | 0.390 |
Why?
|
| Polymorphism, Genetic | 6 | 2012 | 4328 | 0.390 |
Why?
|
| Brain | 15 | 2023 | 26388 | 0.380 |
Why?
|
| Axons | 8 | 1994 | 1685 | 0.380 |
Why?
|
| Epistasis, Genetic | 1 | 2012 | 365 | 0.360 |
Why?
|
| Antioxidants | 4 | 2015 | 1659 | 0.350 |
Why?
|
| NADH Dehydrogenase | 3 | 2004 | 41 | 0.340 |
Why?
|
| Neostriatum | 1 | 2010 | 250 | 0.340 |
Why?
|
| Acetylcysteine | 1 | 2010 | 271 | 0.340 |
Why?
|
| Vesicular Transport Proteins | 4 | 2023 | 377 | 0.330 |
Why?
|
| Neurons | 8 | 2014 | 9340 | 0.330 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2012 | 604 | 0.320 |
Why?
|
| Alzheimer Disease | 6 | 2019 | 8038 | 0.320 |
Why?
|
| Oxidative Stress | 9 | 2023 | 3084 | 0.310 |
Why?
|
| Age of Onset | 9 | 2017 | 3270 | 0.310 |
Why?
|
| Tyrosine 3-Monooxygenase | 3 | 2014 | 375 | 0.300 |
Why?
|
| Retina | 7 | 1994 | 2616 | 0.300 |
Why?
|
| Inheritance Patterns | 2 | 2010 | 340 | 0.290 |
Why?
|
| Electron Transport Complex I | 2 | 2007 | 140 | 0.290 |
Why?
|
| Heat-Shock Proteins | 1 | 2011 | 822 | 0.290 |
Why?
|
| Humans | 111 | 2023 | 744366 | 0.290 |
Why?
|
| Radiopharmaceuticals | 1 | 2016 | 2645 | 0.280 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2007 | 91 | 0.280 |
Why?
|
| Mutation, Missense | 8 | 2010 | 2566 | 0.280 |
Why?
|
| Cadmium | 3 | 2012 | 212 | 0.280 |
Why?
|
| DNA-Binding Proteins | 9 | 2011 | 9647 | 0.270 |
Why?
|
| Sirolimus | 1 | 2013 | 1565 | 0.270 |
Why?
|
| Energy Metabolism | 2 | 2018 | 2897 | 0.270 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2006 | 110 | 0.260 |
Why?
|
| Waiting Lists | 1 | 2009 | 692 | 0.260 |
Why?
|
| Aging, Premature | 2 | 2019 | 47 | 0.260 |
Why?
|
| Genotype | 5 | 2017 | 12952 | 0.260 |
Why?
|
| Interleukin-6 | 1 | 2015 | 3203 | 0.250 |
Why?
|
| Trans-Activators | 2 | 2012 | 2926 | 0.250 |
Why?
|
| Central Nervous System Stimulants | 2 | 2015 | 1148 | 0.250 |
Why?
|
| Neuroglia | 2 | 2012 | 928 | 0.240 |
Why?
|
| Middle Aged | 50 | 2021 | 213390 | 0.240 |
Why?
|
| Cataplexy | 1 | 2004 | 60 | 0.240 |
Why?
|
| Glomerulonephritis | 1 | 2006 | 372 | 0.230 |
Why?
|
| Metallurgy | 3 | 2013 | 94 | 0.230 |
Why?
|
| Frontal Bone | 1 | 2004 | 105 | 0.230 |
Why?
|
| Brain Chemistry | 1 | 2007 | 982 | 0.230 |
Why?
|
| Male | 61 | 2021 | 350115 | 0.230 |
Why?
|
| Nuclear Proteins | 7 | 2011 | 5856 | 0.220 |
Why?
|
| Homeodomain Proteins | 1 | 2012 | 2418 | 0.220 |
Why?
|
| Triage | 1 | 2009 | 977 | 0.220 |
Why?
|
| DNA Mutational Analysis | 9 | 2016 | 4185 | 0.210 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 2873 | 0.210 |
Why?
|
| Aged | 39 | 2021 | 163288 | 0.210 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 2703 | 0.200 |
Why?
|
| Female | 56 | 2021 | 380193 | 0.200 |
Why?
|
| Health Services, Indigenous | 1 | 2021 | 42 | 0.190 |
Why?
|
| Inosine | 1 | 2021 | 133 | 0.190 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2001 | 93 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2021 | 15520 | 0.190 |
Why?
|
| Lead | 4 | 2013 | 852 | 0.180 |
Why?
|
| Lumbar Vertebrae | 1 | 2009 | 1848 | 0.180 |
Why?
|
| Creatinine | 4 | 2013 | 1919 | 0.180 |
Why?
|
| Gene Frequency | 5 | 2012 | 3587 | 0.180 |
Why?
|
| Connective Tissue | 1 | 2021 | 420 | 0.170 |
Why?
|
| Animals | 31 | 2023 | 168768 | 0.170 |
Why?
|
| Ubiquitination | 1 | 2023 | 1012 | 0.170 |
Why?
|
| Diffuse Cerebral Sclerosis of Schilder | 1 | 1998 | 17 | 0.170 |
Why?
|
| Smell | 1 | 2021 | 244 | 0.160 |
Why?
|
| Gait | 1 | 2004 | 793 | 0.160 |
Why?
|
| Adult | 37 | 2021 | 214052 | 0.160 |
Why?
|
| Models, Biological | 2 | 2013 | 9584 | 0.160 |
Why?
|
| Metabolism | 1 | 2019 | 196 | 0.160 |
Why?
|
| Muscle Weakness | 1 | 2021 | 413 | 0.160 |
Why?
|
| Lysosomal Storage Diseases | 1 | 1998 | 79 | 0.150 |
Why?
|
| Neuroimmunomodulation | 1 | 2019 | 157 | 0.150 |
Why?
|
| Glycolipids | 1 | 1998 | 204 | 0.150 |
Why?
|
| Peroxidase | 1 | 2021 | 611 | 0.150 |
Why?
|
| Mice | 13 | 2023 | 81201 | 0.150 |
Why?
|
| Diseases in Twins | 1 | 1999 | 449 | 0.150 |
Why?
|
| Germinal Center | 1 | 2020 | 377 | 0.150 |
Why?
|
| RNA, Transfer | 1 | 2000 | 316 | 0.150 |
Why?
|
| Cell Death | 2 | 2013 | 1707 | 0.150 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2016 | 14 | 0.150 |
Why?
|
| Diagnostic Errors | 1 | 2004 | 1257 | 0.150 |
Why?
|
| Referral and Consultation | 1 | 2009 | 3531 | 0.140 |
Why?
|
| Flavobacteriaceae | 1 | 2016 | 8 | 0.140 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 57776 | 0.140 |
Why?
|
| Cell Count | 2 | 2014 | 1856 | 0.140 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2019 | 555 | 0.140 |
Why?
|
| Treatment Failure | 3 | 2021 | 2618 | 0.140 |
Why?
|
| Constipation | 1 | 2021 | 546 | 0.140 |
Why?
|
| Urbanization | 1 | 2016 | 104 | 0.140 |
Why?
|
| Rheumatology | 1 | 2022 | 576 | 0.140 |
Why?
|
| Occupational Exposure | 4 | 2013 | 1793 | 0.130 |
Why?
|
| United Nations | 1 | 2016 | 165 | 0.130 |
Why?
|
| Inflammation | 3 | 2023 | 10637 | 0.130 |
Why?
|
| Uric Acid | 1 | 2021 | 766 | 0.130 |
Why?
|
| Homozygote | 3 | 2013 | 1787 | 0.130 |
Why?
|
| Antibody Formation | 1 | 2020 | 1402 | 0.130 |
Why?
|
| Injections, Spinal | 1 | 2015 | 303 | 0.130 |
Why?
|
| Reactive Oxygen Species | 4 | 2012 | 2076 | 0.130 |
Why?
|
| Transcription, Genetic | 1 | 2009 | 7721 | 0.120 |
Why?
|
| Carbocyanines | 5 | 1992 | 174 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2020 | 1158 | 0.120 |
Why?
|
| Cataract | 1 | 2001 | 834 | 0.120 |
Why?
|
| Heterozygote | 4 | 2013 | 2804 | 0.120 |
Why?
|
| Conservation of Natural Resources | 1 | 2016 | 204 | 0.120 |
Why?
|
| Infertility | 1 | 2021 | 655 | 0.120 |
Why?
|
| Cities | 1 | 2016 | 513 | 0.120 |
Why?
|
| Biometry | 1 | 2017 | 558 | 0.120 |
Why?
|
| Carnitine | 1 | 2015 | 246 | 0.120 |
Why?
|
| Apolipoproteins E | 2 | 2015 | 1438 | 0.120 |
Why?
|
| Case-Control Studies | 8 | 2021 | 21748 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 1862 | 0.120 |
Why?
|
| Genetic Variation | 3 | 2019 | 6542 | 0.120 |
Why?
|
| Glutamates | 1 | 2015 | 398 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2019 | 970 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2004 | 2916 | 0.120 |
Why?
|
| Nerve Degeneration | 1 | 2018 | 748 | 0.110 |
Why?
|
| Uranium | 1 | 2013 | 19 | 0.110 |
Why?
|
| Mice, Knockout | 4 | 2023 | 14561 | 0.110 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2015 | 440 | 0.110 |
Why?
|
| Dihydro-beta-Erythroidine | 1 | 1992 | 4 | 0.110 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 1 | 2013 | 46 | 0.110 |
Why?
|
| Acetylcholine | 1 | 2015 | 621 | 0.110 |
Why?
|
| Osteoarthritis | 1 | 2021 | 1036 | 0.110 |
Why?
|
| 2-Amino-5-phosphonovalerate | 1 | 1992 | 62 | 0.110 |
Why?
|
| Longitudinal Studies | 7 | 2019 | 13991 | 0.110 |
Why?
|
| Base Sequence | 9 | 2011 | 12797 | 0.110 |
Why?
|
| Aspartic Acid | 1 | 2015 | 576 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 5 | 2010 | 6171 | 0.110 |
Why?
|
| Antimony | 1 | 2012 | 19 | 0.110 |
Why?
|
| Dystonia Musculorum Deformans | 5 | 2010 | 158 | 0.110 |
Why?
|
| Thallium | 1 | 2012 | 101 | 0.110 |
Why?
|
| Ubiquinone | 1 | 2014 | 188 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 4 | 2013 | 2166 | 0.110 |
Why?
|
| Double-Blind Method | 7 | 2022 | 12025 | 0.110 |
Why?
|
| Policy Making | 1 | 2016 | 554 | 0.110 |
Why?
|
| Dizocilpine Maleate | 1 | 1992 | 176 | 0.110 |
Why?
|
| Mice, Transgenic | 4 | 2014 | 9735 | 0.110 |
Why?
|
| Membrane Transport Proteins | 1 | 2018 | 1031 | 0.110 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2012 | 86 | 0.100 |
Why?
|
| Germany | 3 | 2021 | 862 | 0.100 |
Why?
|
| Cohort Studies | 8 | 2021 | 40559 | 0.100 |
Why?
|
| Cartilage, Articular | 1 | 2019 | 1095 | 0.100 |
Why?
|
| Voice Training | 1 | 2012 | 37 | 0.100 |
Why?
|
| Dermatology | 1 | 2022 | 872 | 0.100 |
Why?
|
| Physical Conditioning, Animal | 1 | 2015 | 354 | 0.100 |
Why?
|
| Mitochondrial Myopathies | 2 | 2004 | 47 | 0.100 |
Why?
|
| Deep Brain Stimulation | 1 | 2019 | 748 | 0.100 |
Why?
|
| Brain Diseases | 1 | 2001 | 1563 | 0.100 |
Why?
|
| Inferior Colliculi | 1 | 1992 | 68 | 0.100 |
Why?
|
| Research Personnel | 1 | 2016 | 573 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 2455 | 0.100 |
Why?
|
| NAD | 1 | 2015 | 590 | 0.100 |
Why?
|
| Codon | 5 | 2010 | 611 | 0.100 |
Why?
|
| Biofilms | 1 | 2016 | 617 | 0.100 |
Why?
|
| Craniocerebral Trauma | 1 | 2015 | 482 | 0.100 |
Why?
|
| Adenosine Triphosphate | 3 | 2013 | 2027 | 0.100 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2015 | 1159 | 0.100 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 658 | 0.090 |
Why?
|
| Speech Disorders | 1 | 2012 | 189 | 0.090 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2013 | 231 | 0.090 |
Why?
|
| Genes, Mitochondrial | 1 | 2010 | 61 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2015 | 1460 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 3 | 2012 | 4463 | 0.090 |
Why?
|
| MELAS Syndrome | 1 | 2010 | 50 | 0.090 |
Why?
|
| Likelihood Functions | 1 | 2013 | 1005 | 0.090 |
Why?
|
| Family Health | 4 | 2016 | 1281 | 0.090 |
Why?
|
| Cystatin C | 1 | 2011 | 250 | 0.090 |
Why?
|
| Inclusion Bodies | 2 | 2004 | 279 | 0.090 |
Why?
|
| Retinal Ganglion Cells | 2 | 1992 | 770 | 0.090 |
Why?
|
| Optic Nerve | 2 | 1991 | 554 | 0.090 |
Why?
|
| Mood Disorders | 1 | 2016 | 1106 | 0.090 |
Why?
|
| Gene Expression | 2 | 2015 | 7798 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2010 | 251 | 0.090 |
Why?
|
| Rhabdomyolysis | 1 | 2010 | 150 | 0.090 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 449 | 0.090 |
Why?
|
| Accidental Falls | 1 | 2017 | 1062 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2021 | 2943 | 0.080 |
Why?
|
| Bone Density | 1 | 2021 | 3468 | 0.080 |
Why?
|
| Severity of Illness Index | 8 | 2021 | 15535 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2021 | 23336 | 0.080 |
Why?
|
| Voice Disorders | 1 | 2012 | 276 | 0.080 |
Why?
|
| Oxygen Consumption | 2 | 2013 | 1868 | 0.080 |
Why?
|
| Amino Acid Substitution | 5 | 2010 | 1793 | 0.080 |
Why?
|
| Corpus Striatum | 1 | 2014 | 1221 | 0.080 |
Why?
|
| Psychotherapy, Group | 1 | 2012 | 406 | 0.080 |
Why?
|
| Neuronal Plasticity | 2 | 1994 | 1423 | 0.080 |
Why?
|
| Pedigree | 4 | 2010 | 4642 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 21833 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 4561 | 0.080 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 12961 | 0.080 |
Why?
|
| Glutathione | 1 | 2010 | 590 | 0.080 |
Why?
|
| Cuba | 1 | 2007 | 47 | 0.080 |
Why?
|
| Vision, Ocular | 1 | 1991 | 464 | 0.080 |
Why?
|
| Dependovirus | 1 | 2012 | 706 | 0.080 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2012 | 587 | 0.080 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 1877 | 0.070 |
Why?
|
| DNA Repeat Expansion | 1 | 2007 | 66 | 0.070 |
Why?
|
| Ataxia | 1 | 2009 | 304 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2021 | 3864 | 0.070 |
Why?
|
| Minocycline | 1 | 2008 | 163 | 0.070 |
Why?
|
| Cytosol | 1 | 2010 | 901 | 0.070 |
Why?
|
| Muscle, Skeletal | 3 | 2019 | 4925 | 0.070 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 3154 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 12262 | 0.070 |
Why?
|
| Hot Temperature | 1 | 2013 | 1356 | 0.070 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 2 | 2004 | 41 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 4666 | 0.070 |
Why?
|
| Metabolomics | 1 | 2015 | 1485 | 0.070 |
Why?
|
| Risk Factors | 8 | 2019 | 72296 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2016 | 10252 | 0.070 |
Why?
|
| Molecular Chaperones | 2 | 2009 | 743 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2015 | 9849 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 804 | 0.070 |
Why?
|
| Neurodegenerative Diseases | 3 | 2006 | 1061 | 0.070 |
Why?
|
| Prefrontal Cortex | 1 | 2016 | 2147 | 0.070 |
Why?
|
| Rats | 11 | 2005 | 24252 | 0.070 |
Why?
|
| Neurologic Examination | 2 | 2000 | 931 | 0.070 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2007 | 243 | 0.070 |
Why?
|
| Child | 9 | 2023 | 77709 | 0.070 |
Why?
|
| Mitochondrial Diseases | 1 | 2009 | 320 | 0.070 |
Why?
|
| Heart Rate | 1 | 2017 | 4092 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 1992 | 1178 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2019 | 3116 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2010 | 1525 | 0.070 |
Why?
|
| DNA Damage | 1 | 2015 | 2432 | 0.060 |
Why?
|
| Kidney | 2 | 2011 | 7184 | 0.060 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2007 | 323 | 0.060 |
Why?
|
| Genes, Archaeal | 1 | 2004 | 8 | 0.060 |
Why?
|
| Methanococcus | 1 | 2004 | 10 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2012 | 3001 | 0.060 |
Why?
|
| Liver Transplantation | 2 | 2016 | 2119 | 0.060 |
Why?
|
| Twin Studies as Topic | 1 | 2005 | 105 | 0.060 |
Why?
|
| Cell Line | 2 | 2013 | 16000 | 0.060 |
Why?
|
| Exons | 2 | 2009 | 2439 | 0.060 |
Why?
|
| Astrocytes | 1 | 2012 | 1273 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 12356 | 0.060 |
Why?
|
| Postmortem Changes | 1 | 2004 | 124 | 0.060 |
Why?
|
| Visual Cortex | 1 | 2013 | 1149 | 0.060 |
Why?
|
| Microdissection | 1 | 2004 | 152 | 0.060 |
Why?
|
| Botulinum Toxins | 1 | 2006 | 191 | 0.060 |
Why?
|
| Graft Survival | 2 | 2012 | 3737 | 0.060 |
Why?
|
| Protein Transport | 1 | 2010 | 1988 | 0.060 |
Why?
|
| Cytochromes b | 1 | 2004 | 36 | 0.060 |
Why?
|
| Dementia | 1 | 1998 | 2518 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2013 | 2110 | 0.060 |
Why?
|
| HLA-DQ Antigens | 1 | 2004 | 210 | 0.060 |
Why?
|
| Occupational Diseases | 1 | 2012 | 1469 | 0.060 |
Why?
|
| Neoplasms | 1 | 2013 | 21696 | 0.060 |
Why?
|
| Free Radicals | 1 | 2004 | 237 | 0.060 |
Why?
|
| Cardiomyopathies | 2 | 2010 | 1912 | 0.060 |
Why?
|
| Fluorescent Dyes | 4 | 1992 | 1917 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 1031 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2012 | 2266 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 20130 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2019 | 3712 | 0.060 |
Why?
|
| Tibia | 4 | 2013 | 1077 | 0.060 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2016 | 1433 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2017 | 6442 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 2716 | 0.060 |
Why?
|
| Haplotypes | 1 | 2010 | 2779 | 0.060 |
Why?
|
| Ticks | 1 | 2003 | 70 | 0.060 |
Why?
|
| Longevity | 1 | 2011 | 1071 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2005 | 4751 | 0.060 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2005 | 514 | 0.050 |
Why?
|
| Rats, Inbred Strains | 4 | 1992 | 2186 | 0.050 |
Why?
|
| Electric Stimulation | 1 | 2008 | 1767 | 0.050 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2004 | 108 | 0.050 |
Why?
|
| Beverages | 1 | 2008 | 821 | 0.050 |
Why?
|
| Shock, Septic | 1 | 2009 | 775 | 0.050 |
Why?
|
| Gliosis | 1 | 2023 | 245 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2010 | 3914 | 0.050 |
Why?
|
| Synucleins | 1 | 2002 | 110 | 0.050 |
Why?
|
| Bites and Stings | 1 | 2003 | 91 | 0.050 |
Why?
|
| Kidney Transplantation | 3 | 2016 | 4251 | 0.050 |
Why?
|
| HIV Infections | 3 | 2016 | 16715 | 0.050 |
Why?
|
| Time Factors | 4 | 2017 | 40075 | 0.050 |
Why?
|
| Physical Therapy Modalities | 1 | 2006 | 550 | 0.050 |
Why?
|
| Electron Transport | 1 | 2003 | 211 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 10183 | 0.050 |
Why?
|
| Endemic Diseases | 1 | 2003 | 182 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2012 | 2575 | 0.050 |
Why?
|
| Treatment Outcome | 10 | 2022 | 63107 | 0.050 |
Why?
|
| Gene Rearrangement | 1 | 2007 | 1179 | 0.050 |
Why?
|
| Phosphatidylserines | 1 | 2023 | 193 | 0.050 |
Why?
|
| Northern Territory | 1 | 2021 | 5 | 0.050 |
Why?
|
| Caudate Nucleus | 1 | 2023 | 393 | 0.050 |
Why?
|
| Sweden | 1 | 2005 | 1341 | 0.050 |
Why?
|
| Graft Rejection | 2 | 2012 | 4397 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 5135 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 4 | 1994 | 8300 | 0.050 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2002 | 89 | 0.050 |
Why?
|
| Basal Ganglia Diseases | 1 | 2002 | 149 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 2004 | 4320 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2010 | 2499 | 0.050 |
Why?
|
| Streptococcal Infections | 1 | 2006 | 638 | 0.050 |
Why?
|
| Environmental Pollutants | 1 | 2010 | 1179 | 0.050 |
Why?
|
| Gene Deletion | 1 | 2009 | 2751 | 0.050 |
Why?
|
| Autistic Disorder | 1 | 2010 | 1185 | 0.050 |
Why?
|
| Low Back Pain | 1 | 2009 | 956 | 0.050 |
Why?
|
| Organizations | 1 | 2022 | 170 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 7914 | 0.050 |
Why?
|
| Young Adult | 7 | 2020 | 56429 | 0.050 |
Why?
|
| Sleep, REM | 1 | 2004 | 595 | 0.050 |
Why?
|
| Pandemics | 1 | 2021 | 8385 | 0.050 |
Why?
|
| Comorbidity | 2 | 2019 | 10388 | 0.050 |
Why?
|
| Axonal Transport | 2 | 1992 | 177 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2021 | 53290 | 0.050 |
Why?
|
| Glucose Clamp Technique | 1 | 2021 | 266 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 2 | 2009 | 7182 | 0.050 |
Why?
|
| Cell Survival | 4 | 2020 | 5882 | 0.050 |
Why?
|
| Electroconvulsive Therapy | 1 | 2005 | 477 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 10943 | 0.050 |
Why?
|
| Chemokine CXCL13 | 1 | 2020 | 54 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2012 | 3589 | 0.050 |
Why?
|
| Motor Activity | 1 | 2010 | 2715 | 0.050 |
Why?
|
| Lewy Bodies | 1 | 2000 | 137 | 0.040 |
Why?
|
| Adolescent | 9 | 2015 | 85779 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2001 | 769 | 0.040 |
Why?
|
| Nicotinamide Mononucleotide | 1 | 2019 | 17 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2010 | 41005 | 0.040 |
Why?
|
| Autopsy | 1 | 2023 | 1020 | 0.040 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2019 | 52 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2003 | 1202 | 0.040 |
Why?
|
| Phospholipids | 1 | 2023 | 784 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2020 | 2419 | 0.040 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2019 | 57 | 0.040 |
Why?
|
| Optic Atrophies, Hereditary | 1 | 1999 | 27 | 0.040 |
Why?
|
| Gestational Age | 3 | 1992 | 3493 | 0.040 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2021 | 422 | 0.040 |
Why?
|
| Metacarpophalangeal Joint | 1 | 2019 | 82 | 0.040 |
Why?
|
| Mitochondrial Encephalomyopathies | 1 | 1999 | 37 | 0.040 |
Why?
|
| Rheumatoid Factor | 1 | 2019 | 188 | 0.040 |
Why?
|
| Family | 1 | 2010 | 3147 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2004 | 2971 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2001 | 399 | 0.040 |
Why?
|
| Glucosylceramidase | 1 | 2019 | 125 | 0.040 |
Why?
|
| Myography | 1 | 2019 | 109 | 0.040 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1999 | 158 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2015 | 3444 | 0.040 |
Why?
|
| Risk | 1 | 2011 | 9688 | 0.040 |
Why?
|
| Synaptic Membranes | 1 | 1998 | 91 | 0.040 |
Why?
|
| Lebanon | 1 | 2019 | 229 | 0.040 |
Why?
|
| Blood | 1 | 2001 | 598 | 0.040 |
Why?
|
| Neuropeptides | 1 | 2004 | 942 | 0.040 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2020 | 291 | 0.040 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2018 | 79 | 0.040 |
Why?
|
| Gene Knock-In Techniques | 1 | 2019 | 418 | 0.040 |
Why?
|
| Polyradiculoneuropathy | 1 | 1997 | 64 | 0.040 |
Why?
|
| Chemokine CXCL12 | 1 | 2020 | 465 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 2535 | 0.040 |
Why?
|
| Frontal Lobe | 2 | 1998 | 1406 | 0.040 |
Why?
|
| Dietary Supplements | 1 | 2010 | 3296 | 0.040 |
Why?
|
| Central Nervous System Diseases | 1 | 2002 | 518 | 0.040 |
Why?
|
| Cell Size | 1 | 2019 | 643 | 0.040 |
Why?
|
| Lyme Disease | 1 | 2003 | 621 | 0.040 |
Why?
|
| Apoptosis | 1 | 2013 | 9724 | 0.040 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2018 | 154 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 11726 | 0.040 |
Why?
|
| Kidney Calculi | 1 | 2021 | 465 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2021 | 592 | 0.040 |
Why?
|
| Cell Line, Transformed | 2 | 2009 | 898 | 0.040 |
Why?
|
| Health Education | 1 | 2003 | 1056 | 0.030 |
Why?
|
| Dopamine Agonists | 1 | 1999 | 355 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 2010 | 4232 | 0.030 |
Why?
|
| Genetic Techniques | 1 | 1999 | 435 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 35425 | 0.030 |
Why?
|
| Electric Impedance | 1 | 2019 | 729 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2004 | 4805 | 0.030 |
Why?
|
| Iron | 1 | 2023 | 1774 | 0.030 |
Why?
|
| Cross-Sectional Studies | 4 | 2019 | 25039 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 1999 | 600 | 0.030 |
Why?
|
| Fibroblasts | 2 | 2006 | 4162 | 0.030 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 2646 | 0.030 |
Why?
|
| Color | 1 | 2016 | 307 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2016 | 6366 | 0.030 |
Why?
|
| Pain | 1 | 2009 | 4988 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 14723 | 0.030 |
Why?
|
| Genetic Testing | 2 | 2021 | 3444 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2003 | 1939 | 0.030 |
Why?
|
| Levodopa | 1 | 2014 | 219 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 2004 | 5023 | 0.030 |
Why?
|
| Spleen | 1 | 2020 | 2362 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2020 | 1783 | 0.030 |
Why?
|
| Lysosomes | 1 | 1998 | 893 | 0.030 |
Why?
|
| Serbia | 1 | 2012 | 15 | 0.030 |
Why?
|
| Forecasting | 1 | 2002 | 2951 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2001 | 5181 | 0.030 |
Why?
|
| Acetylglucosaminidase | 1 | 2012 | 70 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2021 | 2682 | 0.030 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 1999 | 770 | 0.030 |
Why?
|
| Causality | 1 | 2019 | 1275 | 0.030 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 39052 | 0.030 |
Why?
|
| Computational Biology | 1 | 2004 | 3519 | 0.030 |
Why?
|
| Lipids | 1 | 2023 | 3307 | 0.030 |
Why?
|
| Speech Therapy | 1 | 2012 | 57 | 0.030 |
Why?
|
| Macrophages | 2 | 2015 | 5660 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 2017 | 672 | 0.030 |
Why?
|
| Drug Implants | 1 | 1992 | 244 | 0.030 |
Why?
|
| Chile | 1 | 2012 | 237 | 0.030 |
Why?
|
| Refugees | 1 | 2019 | 511 | 0.030 |
Why?
|
| Probability | 1 | 2017 | 2506 | 0.030 |
Why?
|
| Polyvinyls | 1 | 1992 | 157 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 1999 | 1504 | 0.030 |
Why?
|
| Abdomen, Acute | 1 | 2012 | 123 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 9955 | 0.020 |
Why?
|
| Untranslated Regions | 1 | 2011 | 31 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 12073 | 0.020 |
Why?
|
| Genome | 1 | 1999 | 1807 | 0.020 |
Why?
|
| Climate Change | 1 | 2016 | 418 | 0.020 |
Why?
|
| Internationality | 1 | 2016 | 1002 | 0.020 |
Why?
|
| Biopsy | 2 | 2004 | 6755 | 0.020 |
Why?
|
| Rhodamines | 1 | 1991 | 183 | 0.020 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2012 | 199 | 0.020 |
Why?
|
| Social Class | 1 | 2019 | 1997 | 0.020 |
Why?
|
| Chemokines | 1 | 2015 | 970 | 0.020 |
Why?
|
| Phenotype | 3 | 2019 | 16367 | 0.020 |
Why?
|
| Neurites | 1 | 1992 | 388 | 0.020 |
Why?
|
| Osteoarthritis, Knee | 1 | 2021 | 1222 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2007 | 19905 | 0.020 |
Why?
|
| Random Allocation | 1 | 2015 | 2428 | 0.020 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2010 | 144 | 0.020 |
Why?
|
| Myeloid Cells | 1 | 2015 | 810 | 0.020 |
Why?
|
| Cognition Disorders | 3 | 2012 | 4043 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 1992 | 313 | 0.020 |
Why?
|
| Light | 1 | 2016 | 1374 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1997 | 2765 | 0.020 |
Why?
|
| Canada | 1 | 2014 | 2065 | 0.020 |
Why?
|
| Logistic Models | 2 | 2017 | 13409 | 0.020 |
Why?
|
| Acute Disease | 1 | 2019 | 7147 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2014 | 1184 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2019 | 4026 | 0.020 |
Why?
|
| Spatial Behavior | 1 | 1989 | 90 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2010 | 18111 | 0.020 |
Why?
|
| Patella | 1 | 2010 | 320 | 0.020 |
Why?
|
| Proteins | 1 | 2004 | 6100 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 1602 | 0.020 |
Why?
|
| Infant | 3 | 2010 | 35134 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 18034 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2009 | 297 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2010 | 319 | 0.020 |
Why?
|
| Cerebral Cortex | 2 | 2005 | 5709 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3778 | 0.020 |
Why?
|
| Schwann Cells | 1 | 1988 | 196 | 0.020 |
Why?
|
| Antibodies | 2 | 2003 | 2460 | 0.020 |
Why?
|
| Research | 1 | 2016 | 1999 | 0.020 |
Why?
|
| Linear Models | 2 | 2012 | 5953 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 2010 | 389 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2017 | 6459 | 0.020 |
Why?
|
| Embryo, Mammalian | 2 | 1991 | 1701 | 0.020 |
Why?
|
| United States | 4 | 2019 | 69872 | 0.020 |
Why?
|
| Age Factors | 2 | 2017 | 18373 | 0.020 |
Why?
|
| Leadership | 1 | 2016 | 1357 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 758 | 0.020 |
Why?
|
| Transplantation, Homologous | 2 | 2010 | 4777 | 0.020 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2010 | 657 | 0.020 |
Why?
|
| CREB-Binding Protein | 1 | 2006 | 151 | 0.020 |
Why?
|
| Catalase | 1 | 2006 | 221 | 0.020 |
Why?
|
| Insulin | 1 | 2021 | 6582 | 0.020 |
Why?
|
| Radiation | 1 | 2005 | 49 | 0.020 |
Why?
|
| Oxidants | 1 | 2006 | 164 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 6036 | 0.020 |
Why?
|
| Seizures | 1 | 1999 | 2859 | 0.020 |
Why?
|
| Brain Mapping | 2 | 1992 | 6670 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 2019 | 3587 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2008 | 536 | 0.020 |
Why?
|
| Nitro Compounds | 1 | 2005 | 74 | 0.020 |
Why?
|
| Species Specificity | 1 | 2010 | 2478 | 0.020 |
Why?
|
| Motor Skills Disorders | 1 | 2005 | 90 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2006 | 255 | 0.020 |
Why?
|
| Visual Pathways | 1 | 1990 | 565 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 9274 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 300 | 0.020 |
Why?
|
| Genome, Archaeal | 1 | 2004 | 18 | 0.020 |
Why?
|
| Propionates | 1 | 2005 | 169 | 0.020 |
Why?
|
| Septum Pellucidum | 1 | 1985 | 58 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2013 | 2232 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 6489 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2019 | 7730 | 0.020 |
Why?
|
| Peroxynitrous Acid | 1 | 2004 | 41 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2010 | 2560 | 0.020 |
Why?
|
| Hippocampus | 2 | 1989 | 3675 | 0.020 |
Why?
|
| Environmental Monitoring | 1 | 2010 | 1414 | 0.010 |
Why?
|
| Response Elements | 1 | 2005 | 312 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2006 | 596 | 0.010 |
Why?
|
| DEET | 1 | 2003 | 10 | 0.010 |
Why?
|
| Insect Repellents | 1 | 2003 | 17 | 0.010 |
Why?
|
| Permethrin | 1 | 2003 | 16 | 0.010 |
Why?
|
| Medication Adherence | 1 | 2015 | 2063 | 0.010 |
Why?
|
| Pamphlets | 1 | 2003 | 75 | 0.010 |
Why?
|
| Software | 1 | 2017 | 4441 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 329 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2006 | 730 | 0.010 |
Why?
|
| Maryland | 1 | 2003 | 276 | 0.010 |
Why?
|
| Functional Laterality | 1 | 1990 | 2290 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1992 | 3749 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2020 | 11486 | 0.010 |
Why?
|
| Calreticulin | 1 | 2003 | 98 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2015 | 3486 | 0.010 |
Why?
|
| Pseudogenes | 1 | 2002 | 113 | 0.010 |
Why?
|
| Electron Transport Complex IV | 1 | 2002 | 189 | 0.010 |
Why?
|
| Physical Endurance | 1 | 2004 | 370 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2005 | 1472 | 0.010 |
Why?
|
| Cell Line, Tumor | 2 | 2009 | 16690 | 0.010 |
Why?
|
| Introns | 1 | 2004 | 992 | 0.010 |
Why?
|
| Artifacts | 1 | 2010 | 1904 | 0.010 |
Why?
|
| Vitamins | 1 | 2009 | 1623 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 2009 | 1456 | 0.010 |
Why?
|
| Sex Factors | 1 | 2014 | 10400 | 0.010 |
Why?
|
| DNA Transposable Elements | 1 | 2004 | 748 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1999 | 5749 | 0.010 |
Why?
|
| Neural Pathways | 1 | 1991 | 2974 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2013 | 6194 | 0.010 |
Why?
|
| Cadaver | 1 | 2004 | 1337 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6539 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 1970 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2004 | 1851 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2015 | 19233 | 0.010 |
Why?
|
| Nerve Regeneration | 1 | 1985 | 788 | 0.010 |
Why?
|
| Muscles | 1 | 2004 | 1614 | 0.010 |
Why?
|
| Memory | 1 | 1989 | 2174 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2012 | 8319 | 0.010 |
Why?
|
| Mitochondrial Proteins | 1 | 2004 | 994 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 13814 | 0.010 |
Why?
|
| Sports | 1 | 2004 | 688 | 0.010 |
Why?
|
| Massachusetts | 1 | 2010 | 8662 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 4153 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 5895 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 12244 | 0.010 |
Why?
|
| Exercise Test | 1 | 2004 | 2073 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 12788 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 5867 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2016 | 77460 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 8436 | 0.010 |
Why?
|
| Glioblastoma | 1 | 2009 | 3481 | 0.010 |
Why?
|
| Incidence | 1 | 2012 | 20952 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 6621 | 0.010 |
Why?
|
| Stem Cells | 1 | 2006 | 3567 | 0.010 |
Why?
|
| Heart | 1 | 2004 | 4464 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 15297 | 0.010 |
Why?
|
| Pregnancy | 1 | 1991 | 29144 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2002 | 6994 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 3922 | 0.010 |
Why?
|
| Liver | 1 | 2004 | 7475 | 0.000 |
Why?
|
| Appetitive Behavior | 1 | 1985 | 37 | 0.000 |
Why?
|
| Graft vs Host Disease | 1 | 1997 | 2958 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 2004 | 25628 | 0.000 |
Why?
|
| Theta Rhythm | 1 | 1985 | 207 | 0.000 |
Why?
|
| Orientation | 1 | 1985 | 327 | 0.000 |
Why?
|
| Discrimination Learning | 1 | 1985 | 280 | 0.000 |
Why?
|
| Epitopes | 1 | 1988 | 2571 | 0.000 |
Why?
|
| Cell Communication | 1 | 1988 | 1621 | 0.000 |
Why?
|
| Action Potentials | 1 | 1989 | 1806 | 0.000 |
Why?
|
| Mental Recall | 1 | 1985 | 1206 | 0.000 |
Why?
|